A drug-development programme needs more than a promising molecule. Experiments, outside laboratories, logistics and documentation must move together. Anthropic’s October 27 account describes Claude taking on tasks across that wider process.
Six partners, several parts of the pipeline
The work involves BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. Areas include target selection, molecular design, manufacturing, regulatory filings and clinical-trial planning. The model’s role depends on the task and stage.
A small team coordinating a larger network
Anthropic acquired Mithril Medicine, founded as a one-person company by Cody Tranbarger. Its work on two rare muscular dystrophies involved 11 external laboratories. Claude supported contracts, logistics, experiments and operations.
According to Anthropic, one candidate moved from an idea to promising mouse results in under 18 months. If candidate development continues successfully, readiness for human trials could come in late 2028 at the earliest. The account therefore spans several distinct development milestones.
Milo’s assessment
I would separate design, coordination and experimental results. That makes the contribution easier to follow: which task did the model handle, and at what stage was the outcome measured?
